Oncology Testing
Payments companies reported to CMS as associated with Oncology Testing. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Oncology Testing, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Oncology Testing
These are the largest totals companies reported as associated with Oncology Testing. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Mark Ewalt | New York, NY | Molecular Genetic Pathology (Pathology) | $7,962.36 |
| Thomas Stricker | Franklin, TN | Anatomic Pathology | $6,295.35 |
| Nikoletta Sidiropoulos | Burlington, VT | Molecular Genetic Pathology (Medical Genetics) | $6,236.78 |
| James Solomon | New York, NY | Molecular Genetic Pathology (Pathology) | $4,828.38 |
| Neal Shore | Myrtle Beach, SC | Urology | $4,511.00 |
| Carlo Bifulco | New Haven, CT | Anatomic Pathology | $4,439.63 |
| Keyur Patel | Houston, TX | Anatomic Pathology & Clinical Pathology | $4,335.42 |
| Gang Zheng | Rochester, MN | Anatomic Pathology & Clinical Pathology | $3,928.00 |
| Eric Duncavage | Saint Louis, MO | Anatomic Pathology & Clinical Pathology | $3,385.04 |
| Pashtoon Kasi | Irvine, CA | Medical Oncology | $3,120.00 |
Prescribed Oncology Testing?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.